Mojia Biotech, a Shanghai, China-based bio-manufacturing firm, raised $80M in Sequence B funding.
The spherical was led by Temasek with participation from LYZZ Capital, Sento Funding, Bits x Bites, Asia Inexperienced Fund.
The corporate intends to make use of the funds to commercialize its Viridimin™ model of animal-feed components, scale up manufacturing capability for Aliphane™ sequence of bio-based supplies, advance its product pipeline and develop its international R&D capabilities.
Led by Ansen Chiew, Mojia Biotech is a product-focused bio-manufacturing firm devoted to the manufacturing of meals elements and chemical supplies utilizing renewable carbon sources and inexperienced processes. Prior to now few years, the corporate has developed revolutionary pathways to supply Viridimin™ model of Vitamin B5. The second product that Mojia Biotech goals to convey to the market is Aliphane™ sequence of biopolymer merchandise, which is extraordinarily versatile and has nice potential in coating and adhesive purposes.
FinSMEs
24/06/2022
